BrainCool AB (publ) acquires patent rights from Dignitana
BrainCoolAB (publ) has acquired, from Dignitana AB (publ), the US patent for the application “cooling of head/neck” in stroke patients. BrainCool has had a license agreement with Dignitana for the patent rights that were established in conjunction with the spin-off of BrainCool to Dignitana’s shareholders in 2014.
The acquisition cost is in line with the cost of registering the patent. The transaction means that BrainCool obtains firmer control of the patent and the coverage of the patent protection as well as increased opportunities to improve the rights concerning the patent. With the acquisition of the patent, BrainCool owns the necessary rights to the technology which is used by the company.
CEO Martin Waleij comments:
- The patent rights for the stroke indication in the US are a great success and important for an upcoming indication in the field where we, among other things, are conducting studies in thrombectomy and where the product IQool™ System is of great interest in the indication.
In the US, patents can be obtained for indications, which is not the case in the European system. Application for patent protection is therefore only filed in the United States.
Dignitana’s CEO, Bill Cronin, comments:
- It has been a pleasure working with Martin and his team on collaborative efforts that further both of our efforts in improving targeted temperature management processes. We are pleased to finalize this transfer that helps enable both firms to sharpen their focus on our core markets.
This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on February 11, 2019.
För mer information
Martin Waleij - VD
+46 - 733 -93 70 76
Om BrainCool AB (publ)
BrainCool AB (publ) är ett innovativt medicinteknikföretag som utvecklar, marknadsför och säljer ledande medicinska kylningssystem för indikationer och områden med betydande medicinska mervärden inom sjukvården. Bolaget fokuserar på två affärsområden, Brain Cooling och Pain Management. BrainCool AB (publ) har sitt säte i Lund. Aktien är noterad på Spotlight Stock Market.